As a rule, it takes three to five years to develop a new medicine, after which the testing phase begins with the participation of volunteers. British startup AI Exscientia and Japanese pharmaceutical company Sumitomo Dainippon Pharma intend to shorten these terms to 1 year.
This is the promising drug DSP-1181 for the treatment of obsessive-compulsive disorder (OCD), a severe mental illness that affects millions of people around the world.
Exscientia, based in Oxford, UK, has a unique machine learning platform called Centaur Chemist. With its help, using AI technology, the company is going to significantly speed up work on the creation of a new drug.
The advantage of this approach is that the AI can analyze millions of molecular combinations and try to determine which ones will be most effective in treating OCD. As a result, faster drug development times will save billions of dollars.